In this 12-week study, once-daily add-on administration of EMPA (25 mg) resulted in significant decreases in HbA1c, FPG, and body weight for Saudi participants with insufficiently controlled T2DM on insulin or OHA. The gene discussed is INS; the disease is type 2 diabetes mellitus.